Search results

  1. Neonatal jaundice

    Everything NICE has said on diagnosing and treating jaundice in newborn babies under 28 days in an interactive flowchart

  2. Headaches

    Everything NICE has said on the most common primary headache disorders in young people aged 12 years and older and adults in an interactive flowchart

  3. Pneumonia

    Everything NICE has said on assessing and managing community- and hospital-acquired pneumonia in an interactive flowchart

  4. Type 1 diabetes in adults

    Everything NICE has said on diagnosing and managing type 1 diabetes in adults in an interactive flowchart

  5. Chronic kidney disease

    Everything NICE has said on chronic kidney disease (renal failure) in an interactive flowchart

  6. Hypertension

    Everything NICE has said on managing hypertension in adults in an interactive flowchart

  7. Diabetes in children and young people

    Everything NICE has said on diagnosing and managing type 1 and 2 diabetes in children and young people in an interactive flowchart

  8. Multiple sclerosis

    Everything NICE has said on multiple sclerosis in an interactive flowchart

  9. Suspected cancer recognition and referral

    Everything NICE has said on suspected cancer, recognition and selection for referral or investigation in primary care in an interactive flowchart

  10. Skin conditions

    Everything NICE has said on managing skin conditions and skin damage in an interactive flowchart

  11. Epilepsy

    Everything NICE has said on diagnosing and managing the epilepsies in adults and children in primary and secondary care in an interactive flowchart

  12. Psychosis and schizophrenia

    Everything NICE has said on recognising and managing psychosis and schizophrenia in children, young people and adults in an interactive flowchart

  13. Low back pain and sciatica

    Everything NICE has said on low back pain and sciatica in an interactive flowchart

  14. Non-Hodgkin's lymphoma

    Everything NICE has said on diagnosing and managing non-Hodgkin's lymphoma in adults and young people 16 years and older in an interactive flowchart

  15. Parkinson's disease

    Everything NICE has said on diagnosing and managing Parkinson's disease in adults in primary and secondary care in an interactive flowchart

  16. Neuropathic pain

    Everything NICE has said on pharmacological management of neuropathic pain in adults in non-specialist settings in an interactive flowchart

  17. Safer insulin prescribing (KTT20)

    This document summarises the evidence base on safer insulin prescribing . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  18. Multimorbidity and polypharmacy (KTT18)

    This document summarises the evidence base on multimorbidity and polypharmacy . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  19. Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)

    This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on anticoagulants , including direct-acting oral anticoagulants (DOACs). It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  20. Biosimilar medicines (KTT15)

    The key therapeutic topic biosimilar medicines has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .

  21. Wound care products (KTT14)

    This document summarises the evidence base on wound care products . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  22. Non-steroidal anti-inflammatory drugs (KTT13)

    The key therapeutic topic non-steroidal anti-inflammatory drugs has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .

  23. Antipsychotics in people living with dementia (KTT7)

    This document summarises the evidence base on antipsychotics in people living with dementia . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  24. Hypnotics (KTT6)

    This document summarises the evidence base on hypnotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  25. Asthma: medicines safety priorities (KTT5)

    This document summarises the evidence base on asthma: medicines safety priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  26. Lipid-modifying drugs (KTT3)

    This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on lipid-modifying drugs. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  27. Shared decision making (KTT23)

    This document summarises the evidence base on shared decision making . It is a key therapeutic topic that has been identified to support Medicines Optimisation. It is not formal NICE guidance .

  28. Chemotherapy dose standardisation (KTT22)

    This document summarises the evidence base on chemotherapy dose standardisation . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  29. Type 2 diabetes mellitus: medicines optimisation priorities (KTT12)

    This document summarises the evidence base on type 2 diabetes mellitus: medicines optimisation priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .